keyword
https://read.qxmd.com/read/38523536/the-relationship-between-statin-intake-and-risk-of-pancreatic-cancer-a-systematic-review-and-meta-analysis
#1
Hesamaldin Bagheri, Omid-Ali Adeli, Saeid Heidari-Soureshjani, Zahra Azadegan-Dehkordi, Catherine Mt Sherwin
BACKGROUND: Pancreatic neoplasm is one of the types of cancer with a high incidence and case-fatality rate. OBJECTIVES: This study was designed to investigate the relationship between statin intake and the risk of pancreatic cancer with a systematic review and meta-analysis approach. METHODS: This study was a systematic review and meta-analysis of studies published before 2023 in Cochrane Library, Web of Science (WOS), PubMed, Google Scholar, ScienceDirect, Scopus, and Embase databases...
March 20, 2024: Current Drug Research Reviews
https://read.qxmd.com/read/38069135/lovastatin-treatment-inducing-apoptosis-in-human-pancreatic-cancer-cells-by-inhibiting-cholesterol-rafts-in-plasma-membrane-and-mitochondria
#2
JOURNAL ARTICLE
Momoko Gyoten, Yi Luo, Rina Fujiwara-Tani, Shiori Mori, Ruiko Ogata, Shingo Kishi, Hiroki Kuniyasu
Resistance to anticancer drugs is a problem in the treatment of pancreatic ductal carcinoma (PDAC) and overcoming it is an important issue. Recently, it has been reported that statins induce apoptosis in cancer cells but the mechanism has not been completely elucidated. We investigated the antitumor mechanisms of statins against PDAC and their impact on resistance to gemcitabine (GEM). Lovastatin (LOVA) increased mitochondrial oxidative stress in PDAC cells, leading to apoptosis. LOVA reduced lipid rafts in the plasma membrane and mitochondria, suppressed the activation of epithelial growth factor receptor (EGFR) and AKT in plasma membrane rafts, and reduced B-cell lymphoma 2 (BCL2)-Bcl-2-associated X protein (BAX) binding and the translocation of F1F0 ATPase in mitochondrial rafts...
November 27, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/38029455/organic-selenium-induces-ferroptosis-in-pancreatic-cancer-cells
#3
JOURNAL ARTICLE
Roberta Noè, Noemi Inglese, Patrizia Romani, Thauan Serafini, Carlotta Paoli, Beatrice Calciolari, Marco Fantuz, Agata Zamborlin, Nicoletta C Surdo, Vittoria Spada, Martina Spacci, Sara Volta, Maria Laura Ermini, Giulietta Di Benedetto, Valentina Frusca, Claudio Santi, Konstantinos Lefkimmiatis, Sirio Dupont, Valerio Voliani, Luca Sancineto, Alessandro Carrer
Pancreatic ductal adenocarcinoma (PDA) cells reprogram both mitochondrial and lysosomal functions to support growth. At the same time, this causes significant dishomeostasis of free radicals. While this is compensated by the upregulation of detoxification mechanisms, it also represents a potential vulnerability. Here we demonstrate that PDA cells are sensitive to the inhibition of the mevalonate pathway (MVP), which supports the biosynthesis of critical antioxidant intermediates and protect from ferroptosis...
November 20, 2023: Redox Biology
https://read.qxmd.com/read/37958351/cholesterol-metabolism-in-pancreatic-cancer
#4
REVIEW
Artur Rebelo, Jörg Kleeff, Yoshiaki Sunami
Pancreatic cancer's substantial impact on cancer-related mortality, responsible for 8% of cancer deaths and ranking fourth in the US, persists despite advancements, with a five-year relative survival rate of only 11%. Forecasts predict a 70% surge in new cases and a 72% increase in global pancreatic cancer-related deaths by 2040. This review explores the intrinsic metabolic reprogramming of pancreatic cancer, focusing on the mevalonate pathway, including cholesterol biosynthesis, transportation, targeting strategies, and clinical studies...
October 27, 2023: Cancers
https://read.qxmd.com/read/37926727/statins-abrogate-gemcitabine-induced-pd-l1-expression-in-pancreatic-cancer-associated-fibroblasts-and-cancer-cells-with-improved-therapeutic-outcome
#5
JOURNAL ARTICLE
Aliva Prity Minz, Debasish Mohapatra, Madhuri Dutta, Manisha Sethi, Deepti Parida, Amlan Priyadarshee Mohapatra, Swayambara Mishra, Salona Kar, Prakash K Sasmal, Shantibhusan Senapati
A combination of chemotherapy with immunotherapy has been proposed to have better clinical outcomes in Pancreatic Ductal Adenocarcinoma (PDAC). On the other hand, chemotherapeutics is known to have certain unwanted effects on the tumor microenvironment that may mask the expected beneficial effects of immunotherapy. Here, we have investigated the effect of gemcitabine (GEM), on two immune checkpoint proteins (PD-L1 and PD-L2) expression in cancer associated fibroblasts (CAFs) and pancreatic cancer cells (PCCs)...
November 5, 2023: Cancer Immunology, Immunotherapy: CII
https://read.qxmd.com/read/37752238/low-dosage-combination-treatment-with-metformin-and-simvastatin-inhibits-obesity-promoted-pancreatic-cancer-development-in-male-krasg12d-mice
#6
JOURNAL ARTICLE
Yaroslav Teper, Linda Ye, Richard T Waldron, Aurelia Lugea, Xiaoying Sun, James Sinnett-Smith, Oscar J Hines, Stephen J Pandol, Enrique Rozengurt, Guido Eibl
Pancreatic ductal adenocarcinoma (PDAC), a highly lethal disease with limited therapeutic options, may benefit from repurposing of FDA-approved drugs in preventive or interceptive strategies in high-risk populations. Previous animal studies demonstrated that the use of metformin and statins as single agents at relatively high doses restrained PDAC development. Here, four-week-old mice expressing KrasG12D in all pancreatic lineages (KC mice) and fed an obesogenic high fat, high calorie diet that promotes early PDAC development were randomized onto low dosage metformin, simvastatin, or both drugs in combination administered orally...
September 26, 2023: Scientific Reports
https://read.qxmd.com/read/37740766/impact-of-preoperative-statin-medication-on-long-term-outcomes-after-pancreatoduodenectomy-for-ductal-adenocarcinoma-an-international-multicentric-cross-sectional-study
#7
JOURNAL ARTICLE
Gaëtan-Romain Joliat, Sérgio Gaspar-Figueiredo, Ismail Labgaa, Dionisios Vrochides, Julie Perinel, Mustapha Adham, Nicolas Demartines, Markus Schäfer
PURPOSE: Statin treatment has been shown in certain population studies and meta-analyses to improve survival of patients with pancreatic ductal adenocarcinoma (PDAC). This study assessed if patients with statin treatment had better overall survival (OS) and disease-free survival (DFS) after upfront pancreatoduodenectomy for PDAC. METHODS: Consecutive PDAC patients were retrospectively collected from three centers in Europe and USA (study period: 2000-2017). Adult patients who underwent upfront pancreatoduodenectomy and survived the first 90 postoperative days were included...
September 23, 2023: Journal of Cancer Research and Clinical Oncology
https://read.qxmd.com/read/37664034/the-effects-of-statins-in-patients-with-advanced-stage-cancers-%C3%A2-a-systematic-review-and-meta-analysis
#8
Qiang Zhou, Zhihua Jiao, Yuxi Liu, Peter N Devreotes, Zhenyu Zhang
BACKGROUND: Statin therapy has been shown to reduce mortality in a wide range of cancer types and overall stages. Still, there is uncertainty about its efficacy in increasing survival among advanced cancer patients. METHODS: We conducted a meta-analysis with data from all studies that compared the hazard ratio of overall survival, cancer-specific survival, and progression-free survival in patients with advanced-stage cancer who receive statin therapy. Studies were selected from the PubMed, Embase, and Web of Science databases from their inception to December 31, 2022...
2023: Frontiers in Oncology
https://read.qxmd.com/read/37622694/a-systematic-review-and-meta-analysis-on-the-role-of-statins-in-the-prevention-of-mortality-following-pancreatic-cancer
#9
Khatereh Anbari, Mehdi Mohammadian Amiri, Saeid Heidari-Soureshjani, Catherine Mt Sherwin, Karamali Kasiri
BACKGROUND: Pancreatic cancer (PC) is a type of cancer with a high incidence and case-fatality rate. OBJECTIVE: This study aimed to evaluate the role of statins in preventing mortality following PC based on scientific evidence with systematic review and meta-analysis method. METHODS: This meta-analysis considered studies published from 1980 till the end of 2022 in ISI Web of Science, Scopus, PubMed, Cochrane, Science Direct, Google Scholar, and Embase databases...
August 24, 2023: Anti-cancer Agents in Medicinal Chemistry
https://read.qxmd.com/read/37293171/statins-exert-anti-growth-effects-by-suppressing-yap-taz-expressions-via-jnk-signal-activation-and-eliminate-the-immune-suppression-by-downregulating-pd-l1-expression-in-pancreatic-cancer
#10
JOURNAL ARTICLE
Norio Uemura, Hiromitsu Hayashi, Zhao Liu, Kazuki Matsumura, Yoko Ogata, Noriko Yasuda, Hiroki Sato, Yuta Shiraishi, Tatsunori Miyata, Shigeki Nakagawa, Kosuke Mima, Hidetoshi Nitta, Hideo Baba
Statins are cholesterol-lowering agents that act as inhibitors of 3-hydroxy-3-methyl-glutaryl-coenzymeA (HMG CoA) reductase. Recently, statins have received a lot of attention, especially regarding how statins act on the immune system. Here, the clinical impact of statin intake was examined in patients with resected pancreatic cancer, and the underlying mechanisms were investigated in vitro and in vivo . We found that statin intake was associated with favorable prognostic outcomes in patients with resectable pancreatic cancer...
2023: American Journal of Cancer Research
https://read.qxmd.com/read/37261185/acute-pancreatitis-secondary-to-pembrolizumab-induced-hypertriglyceridemia
#11
Ammar Ashfaq, Nishanth Thalambedu, Muhammad Umair Atiq
Pembrolizumab is a humanized monoclonal antibody targeted against programmed cell death protein 1 (PD-1) receptor of lymphocytes. It is used alone or in combination with many chemotherapy regimens for a wide variety of cancers. It has been reported to cause various side effects including endocrinopathies, colitis, rash, and pneumonitis. Hypertriglyceridemia (HTG) has been recently added to its side effect profile with a possible pathogenic mechanism involving autoantibodies against glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 (GP1HBP1)...
April 2023: Curēus
https://read.qxmd.com/read/37140101/a-proteomic-signature-and-potential-pharmacological-opportunities-in-the-adaptive-resistance-to-mek-and-pi3k-kinase-inhibition-in-pancreatic-cancer-cells
#12
JOURNAL ARTICLE
Alain Aguilar-Valdés, Francisco González-Vela, Hilda Sánchez-Vidal, Juan Martínez-Aguilar
Pancreatic cancer is one of the most lethal cancer types and is becoming a leading cause of cancer-related deaths. The limited benefit offered by chemotherapy agents has propelled the search for alternative approaches that target specific molecular drivers of cancer growth and progression. Mutant KRas and effector pathways Raf/MEK/ERK and PI3K/Akt are key players in pancreatic cancer; however, preclinical studies have shown adaptive tumour response to combined MEK and PI3K kinase inhibition leading to treatment resistance...
May 4, 2023: Proteomics
https://read.qxmd.com/read/36711701/statin-prevents-cancer-development-in-chronic-inflammation-by-blocking-interleukin-33-expression
#13
Jong Ho Park, Mahsa Mortaja, Heehwa Son, Marjan Azin, Jun Wang, Michael Collier, Anna Mandinova, Yevgeniy Semenov, Mari Mino-Kenudson, Shadmehr Demehri
Chronic inflammation is a major cause of cancer worldwide. Interleukin 33 (IL-33) is a critical initiator of cancer-prone chronic inflammation; however, its induction mechanism by the environmental causes of chronic inflammation is unknown. Herein, we demonstrate that Toll-like receptor (TLR)3/4-TBK1-IRF3 pathway activation links environmental insults to IL-33 induction in the skin and pancreas. FDA-approved drug library screen identified pitavastatin as an effective IL-33 inhibitor by blocking TBK1 membrane recruitment/activation through the mevalonate pathway inhibition...
January 12, 2023: Research Square
https://read.qxmd.com/read/36672448/biological-and-clinical-impacts-of-glucose-metabolism-in-pancreatic-ductal-adenocarcinoma
#14
REVIEW
Zhao Liu, Hiromitsu Hayashi, Kazuki Matsumura, Norio Uemura, Yuta Shiraishi, Hiroki Sato, Hideo Baba
Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer type as it is prone to metastases and is difficult to diagnose at an early stage. Despite advances in molecular detection, its clinical prognosis remains poor and it is expected to become the second leading cause of cancer-related deaths. Approximately 85% of patients develop glucose metabolism disorders, most commonly diabetes mellitus, within three years prior to their pancreatic cancer diagnosis. Diabetes, or glucose metabolism disorders related to PDAC, are typically associated with insulin resistance, and beta cell damage, among other factors...
January 13, 2023: Cancers
https://read.qxmd.com/read/36579985/selected-statins-as-dual-antiproliferative-antiinflammatory-compounds
#15
JOURNAL ARTICLE
Buchra Haj Hussein, Violet Kasabri, Yusuf Al-Hiari, Shereen Arabiyat, Balqis Ikhmais, Sundus Alalawi, Tariq Al-Qirim
BACKGROUND: We hypothesized that superlative dual cytotoxicity-antiinflammtion bioefficacies of 9 selected lipophilic statins correlate to their chelation effect of 3,5-dihydroxyheptanoic acid. METHODOLOGY: Lipophilic-acid chelating statins have been screened for in vitro duality of proliferation inhibition and NO-radical scavenging capacities. RESULTS: Their spectrum of selectivity indices for safety in PDL fibroblasts -based 72h incubations was reported...
December 1, 2022: Asian Pacific Journal of Cancer Prevention: APJCP
https://read.qxmd.com/read/36422538/simvastatin-attenuated-tumor-growth-in-different-pancreatic-tumor-animal-models
#16
JOURNAL ARTICLE
Chao-Yi Chen, Yi-Feng Yang, Paul C Wang, Liang Shan, Stephen Lin, Po-Jung Chen, Yi-Jung Chen, Han-Sun Chiang, Jaw-Town Lin, Chi-Feng Hung, Yao-Jen Liang
Newly diagnosed pancreatic cancer increases year by year, while the prognosis of pancreatic cancer has not been very good. Statin drugs were found to have protective effects against a variety of cancers, but their association with pancreatic cancer remains to be clarified. This study used different pancreatic cancer cell lines and in different animal models to confirm the relationship between simvastatin and pancreatic cancer. Flow cytometry and luciferase-based bioluminescent images were used to investigate the cell cycle and tumor growth changes under simvastatin treatment...
November 14, 2022: Pharmaceuticals
https://read.qxmd.com/read/36313271/statins-inhibit-inflammatory-cytokine-production-by-macrophages-and-acinar-to-ductal-metaplasia-of-pancreatic-cells
#17
JOURNAL ARTICLE
Soichiro Ako, Yaroslav Teper, Linda Ye, James Sinnett-Smith, Oscar J Hines, Enrique Rozengurt, Guido Eibl
BACKGROUND AND AIMS: Animal data show that the presence of an oncogenic Kras mutation in pancreatic acinar cells leads to acinar-to-ductal metaplasia (ADM), pancreatic intraepithelial neoplasia (PanIN), and pancreatic ductal adenocarcinoma (PDAC). Inflammatory macrophages play an important role in the formation of ADMs and transition to PanINs. Epidemiologically, statins are associated with a reduced risk of PDAC. We investigated whether statins inhibit inflammatory cytokine production in macrophages and whether this leads to reduced ADM formation...
2022: Gastro Hep Adv
https://read.qxmd.com/read/35800820/an-update-on-common-pharmaceuticals-in-the-prevention-of-pancreatic-cancer
#18
REVIEW
Candace Miyaki, Launa M Lynch
In this review, we aim to update readers about the most recent studies on common pharmaceuticals and their association with pancreatic cancer risk. The use of prophylactic aspirin, metformin, beta-blockers, and statins has been studied in the past but showed inconclusive results in the reduction of pancreatic cancer incidence. However, in recent studies, these medications along with combination therapy of aspirin and metformin were found to have a more significant association with decreasing risk. Given the poor prognosis of pancreatic cancer despite treatment, medication prophylaxis prevention should be considered...
May 2022: Curēus
https://read.qxmd.com/read/35591892/not-a-statin-induced-myopathy-metastatic-pancreatic-adenocarcinoma-presenting-as-paraneoplastic-myositis
#19
Gonca Ozcan, Anjiya Shaikh, Erica Becker, Nikola Perosevic
Polymyositis is an inflammatory disease that causes bilateral proximal muscle weakness; unlike dermatomyositis, it is not usually associated with malignancy. However, there are a handful of case reports documenting polymyositis in patients with lymphoma, breast, lung, and bladder cancer. Here we report a case of metastatic pancreatic adenocarcinoma disguised by presenting as polymyositis. Clinical presentation, laboratory values, muscle biopsy, and imaging were all diagnostic of paraneoplastic polymyositis...
May 2022: Curēus
https://read.qxmd.com/read/35551139/risk-factors-for-nab-paclitaxel-and-gemcitabine-induced-peripheral-neuropathy-in-patients-with-pancreatic-cancer
#20
MULTICENTER STUDY
Martina Catalano, Monica Ramello, Raffaele Conca, Giuseppe Aprile, Roberto Petrioli, Giandomenico Roviello
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent adverse events observed with taxane use, whose disability often required modification or treatment discontinuation. The aim of this study was to assess the value of several variables as risk factors for CIPN development. MATERIAL AND METHODS: Eligible patients with metastatic pancreatic cancer receiving chemotherapy with nab-paclitaxel and gemcitabine were assessed in a multicenter study...
2022: Oncology
keyword
keyword
83937
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.